I think due to PFS results and crossovers, the market wrongly assumes that the burden of proof lies with the naysayers. Dont forget that the PFS results in an open label P2 study should be discounted slightly and the # of crossovers should not cancel nearly all the OS benefits.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.